Cargando…
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–25 years, for up to 3 years (HPV-070 study) and up to 5...
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500548/ https://www.ncbi.nlm.nih.gov/pubmed/30715452 http://dx.doi.org/10.1093/infdis/jiy743 |
| _version_ | 1783415969581891584 |
|---|---|
| author | Folschweiller, Nicolas Behre, Ulrich Dionne, Marc Durando, Paolo Esposito, Susanna Ferguson, Linda Ferguson, Murdo Hillemanns, Peter McNeil, Shelly A Peters, Klaus Ramjattan, Brian Schwarz, Tino F Supparatpinyo, Khuanchai Suryakirian, Pemmaraju V Janssens, Michel Moris, Philippe Decreux, Annabelle Poncelet, Sylviane Struyf, Frank |
| author_facet | Folschweiller, Nicolas Behre, Ulrich Dionne, Marc Durando, Paolo Esposito, Susanna Ferguson, Linda Ferguson, Murdo Hillemanns, Peter McNeil, Shelly A Peters, Klaus Ramjattan, Brian Schwarz, Tino F Supparatpinyo, Khuanchai Suryakirian, Pemmaraju V Janssens, Michel Moris, Philippe Decreux, Annabelle Poncelet, Sylviane Struyf, Frank |
| author_sort | Folschweiller, Nicolas |
| collection | PubMed |
| description | This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4(+) T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970. |
| format | Online Article Text |
| id | pubmed-6500548 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65005482019-05-08 Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine Folschweiller, Nicolas Behre, Ulrich Dionne, Marc Durando, Paolo Esposito, Susanna Ferguson, Linda Ferguson, Murdo Hillemanns, Peter McNeil, Shelly A Peters, Klaus Ramjattan, Brian Schwarz, Tino F Supparatpinyo, Khuanchai Suryakirian, Pemmaraju V Janssens, Michel Moris, Philippe Decreux, Annabelle Poncelet, Sylviane Struyf, Frank J Infect Dis Major Articles and Brief Reports This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4(+) T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970. Oxford University Press 2019-06-01 2019-02-03 /pmc/articles/PMC6500548/ /pubmed/30715452 http://dx.doi.org/10.1093/infdis/jiy743 Text en © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Major Articles and Brief Reports Folschweiller, Nicolas Behre, Ulrich Dionne, Marc Durando, Paolo Esposito, Susanna Ferguson, Linda Ferguson, Murdo Hillemanns, Peter McNeil, Shelly A Peters, Klaus Ramjattan, Brian Schwarz, Tino F Supparatpinyo, Khuanchai Suryakirian, Pemmaraju V Janssens, Michel Moris, Philippe Decreux, Annabelle Poncelet, Sylviane Struyf, Frank Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine |
| title | Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine |
| title_full | Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine |
| title_fullStr | Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine |
| title_full_unstemmed | Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine |
| title_short | Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine |
| title_sort | long-term cross-reactivity against nonvaccine human papillomavirus types 31 and 45 after 2- or 3-dose schedules of the as04-adjuvanted human hpv-16/18 vaccine |
| topic | Major Articles and Brief Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500548/ https://www.ncbi.nlm.nih.gov/pubmed/30715452 http://dx.doi.org/10.1093/infdis/jiy743 |
| work_keys_str_mv | AT folschweillernicolas longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT behreulrich longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT dionnemarc longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT durandopaolo longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT espositosusanna longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT fergusonlinda longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT fergusonmurdo longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT hillemannspeter longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT mcneilshellya longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT petersklaus longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT ramjattanbrian longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT schwarztinof longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT supparatpinyokhuanchai longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT suryakirianpemmarajuv longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT janssensmichel longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT morisphilippe longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT decreuxannabelle longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT ponceletsylviane longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine AT struyffrank longtermcrossreactivityagainstnonvaccinehumanpapillomavirustypes31and45after2or3doseschedulesoftheas04adjuvantedhumanhpv1618vaccine |